These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 26345389

  • 21. A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy.
    McKiernan J, Noerholm M, Tadigotla V, Kumar S, Torkler P, Sant G, Alter J, Donovan MJ, Skog J.
    BMC Urol; 2020 Sep 01; 20(1):138. PubMed ID: 32873277
    [Abstract] [Full Text] [Related]

  • 22. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue.
    Stephan C, Jung M, Rabenhorst S, Kilic E, Jung K.
    Clin Chem Lab Med; 2015 Jun 01; 53(7):1109-18. PubMed ID: 25720086
    [Abstract] [Full Text] [Related]

  • 23. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.
    Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama S, Tomita K, Umekawa T, Uemura H, Miki T.
    BJU Int; 2013 May 01; 111(6):928-33. PubMed ID: 23331404
    [Abstract] [Full Text] [Related]

  • 24. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
    Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, Denton BT.
    Cancer; 2015 Nov 15; 121(22):4071-9. PubMed ID: 26280815
    [Abstract] [Full Text] [Related]

  • 25. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer.
    Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M, Llauradó M, Colás E, Pedrola N, Montes M, Sequeiros T, Ertekin T, Majem B, Planas J, Ruiz A, Abal M, Sánchez A, Morote J, Reventós J, Doll A.
    Prostate; 2011 Dec 15; 71(16):1736-45. PubMed ID: 21520154
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Thompson I, Carroll P.
    Eur Urol; 2018 Dec 15; 74(6):731-738. PubMed ID: 30237023
    [Abstract] [Full Text] [Related]

  • 31. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
    Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, Rittmaster RS, Andriole GL, Groskopf J.
    Urology; 2011 Aug 15; 78(2):380-5. PubMed ID: 21820580
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer.
    Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K.
    Prostate Cancer Prostatic Dis; 2012 Mar 15; 15(1):100-5. PubMed ID: 22042252
    [Abstract] [Full Text] [Related]

  • 34. High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy after a previous negative standard biopsy.
    De Luca S, Passera R, Cattaneo G, Manfredi M, Mele F, Fiori C, Bollito E, Cirillo S, Porpiglia F.
    BJU Int; 2016 Nov 15; 118(5):723-730. PubMed ID: 27112799
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS).
    Newcomb LF, Zheng Y, Faino AV, Bianchi-Frias D, Cooperberg MR, Brown MD, Brooks JD, Dash A, Fabrizio MD, Gleave ME, Liss M, Morgan TM, Thompson IM, Wagner AA, Carroll PR, Nelson PS, Lin DW.
    Prostate Cancer Prostatic Dis; 2019 Sep 15; 22(3):438-445. PubMed ID: 30664734
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.